# ADULT MEDICATION GUIDELINE

## PARECOXIB

| Scope (Staff): | All WNHS Staff |
| Scope (Area): | Obstetrics and Gynaecology |

This document should be read in conjunction with the Disclaimer.

### Quick Links

<table>
<thead>
<tr>
<th>Dose</th>
<th>Administration</th>
<th>Monitoring</th>
<th>Pregnancy and Breastfeeding</th>
</tr>
</thead>
</table>

### Restrictions

Formulary: Unrestricted

### Medication Class

Nonsteroidal Anti-inflammatory Drug (NSAID)

### Presentation

Vial: 40mg

### Storage

Store at room temperature, below 25°C

### Dose

**Postoperative Pain**

**IV/IM:**

40mg as a single dose

*In patients >65yrs and <50kg or with moderate hepatic impairment:*

20mg as a single dose
## Administration

**Step 1 Reconstitution:**

**IV/IM**

Reconstitute the vial with 2 mL of sodium chloride 0.9%, glucose 5% or glucose 5% in sodium chloride 0.45%; the solution is clear and colourless.

**Step 2 Administration:**

**IV injection**

Inject over a few seconds

**IM injection**

Inject slowly and deep into the muscle

## Monitoring

**Renal:** Avoid use if CrCl <25 mL/minute

**Hepatic:** Contraindicated in severe impairment; reduce dose in moderate impairment (Child-Pugh score 7–9) as elimination is decreased

**Elderly:** Reduce dose for elderly women <50 kg

## Pregnancy

1st Trimester: Consider alternative

2nd Trimester: Consider alternative

3rd Trimester: Consider alternative

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

## Breastfeeding

Considered safe to use

## Comments

Regular oral NSAIDs may be commenced 12 hours after IV parecoxib.
Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

The Hitchhikers Guide to Obstetric Anaesthesia

WNHS Pharmaceutical and Medicines Management Guidelines:

WNHS Medication Administration Guideline

WNHS Medication Management Guideline “Return and Disposal of Medications”

References


<table>
<thead>
<tr>
<th>Keywords</th>
<th>Parecoxib</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Owner</td>
<td>Chief Pharmacist</td>
</tr>
<tr>
<td>Author/Reviewer</td>
<td>KEMH Pharmacy Department</td>
</tr>
<tr>
<td>Version Info</td>
<td>4.1 – Comments updated</td>
</tr>
<tr>
<td>Date First Issued:</td>
<td>20/09/2007</td>
</tr>
<tr>
<td>Endorsed by</td>
<td>Medicines and Therapeutics Committee</td>
</tr>
<tr>
<td>NSQHS Standards Applicable:</td>
<td>Std 1: Clinical Governance</td>
</tr>
<tr>
<td></td>
<td>Std 2: Partnering with Consumers</td>
</tr>
<tr>
<td></td>
<td>Std 6: Communicating for Safety</td>
</tr>
<tr>
<td></td>
<td>Std 3: Preventing and Controlling Healthcare Associated Infection</td>
</tr>
<tr>
<td></td>
<td>Std 7: Blood Management</td>
</tr>
<tr>
<td></td>
<td>Std 4: Medication Safety</td>
</tr>
<tr>
<td></td>
<td>Std 8: Recognising and Responding to Acute Deterioration</td>
</tr>
</tbody>
</table>

Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2021

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.